Evaluation of Prognostic Factors and Validation of Tumor Response Ratios after Neoadjuvant Chemotherapy in Patients with Breast Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: In the treatment of breast cancer, neoadjuvant chemotherapy (NAC) is useful to reduce breast cancer size before surgical intervention. Patients who achieve a pathologic complete response (pCR) to NAC have improved overall survival (OS). However, the relationship between prognosis and partial response is yet unclear. In this study, we evaluated prognostic factors and the tumor response ratio (TRR) method among patients who received NAC. Methods: Clinicopathologic factors were evaluated to predict OS. The TRR was calculated by dividing pathologic tumor size by clinical tumor size. TRRs were then categorized into four groups, and the survival times for the different TRR groups were compared using statistical evaluation. Results: Clinical N stage (p=0.02), overall stage (p=0.04), pathologic N stage (p=0.03), hormone receptor status (p=0.01), and lymphovascular invasion (p=0.02) were significantly associated with OS. Pathologic overall stage and TRR did not correlate with OS. Patients with a pCR exhibited the best survival rates using the current staging system and the TRR method. Conclusion: Clinicopathologic factors can be easily applied to predict OS, and clinicians could use these parameters until an accurate, simple, and highly discriminatory methods is developed to assess breast cancer patients with a partial.
Abstract
Purpose: In the treatment of breast cancer, neoadjuvant chemotherapy (NAC) is useful to reduce breast cancer size before surgical intervention. Patients who achieve a pathologic complete response (pCR) to NAC have improved overall survival (OS). However, the relationship between prognosis and partial response is yet unclear. In this study, we evaluated prognostic factors and the tumor response ratio (TRR) method among patients who received NAC. Methods: Clinicopathologic factors were evaluated to predict OS. The TRR was calculated by dividing pathologic tumor size by clinical tumor size. TRRs were then categorized into four groups, and the survival times for the different TRR groups were compared using statistical evaluation. Results: Clinical N stage (p=0.02), overall stage (p=0.04), pathologic N stage (p=0.03), hormone receptor status (p=0.01), and lymphovascular invasion (p=0.02) were significantly associated with OS. Pathologic overall stage and TRR did not correlate with OS. Patients with a pCR exhibited the best survival rates using the current staging system and the TRR method. Conclusion: Clinicopathologic factors can be easily applied to predict OS, and clinicians could use these parameters until an accurate, simple, and highly discriminatory methods is developed to assess breast cancer patients with a partial.
참고문헌 (21)
- Bonadonna G, "Are surgical adjuvant trials altering the course of breast cancer?", Semin Oncol, 5, pp.450~464 (1978)
- Kantarjian HM, "The management of locally advanced breast cancer: a combined modality approach", Eur J Cancer Clin Oncol, 20, pp.1353~1361 (1984)
- Rastogi P, "Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
- Berruti A, "International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)", J Natl Cancer Inst Monogr, 2011, pp.147~151 (2011)
- Bonadonna G, "Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more", J Natl Cancer Inst, 82, pp.1539~1545 (1990)
- Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
- Fisher B, "Effect of preoperative chemotherapy on the outcome of women with operable breast cancer", J Clin Oncol, 16, pp.2672~2685 (1998)
- Kuerer HM, "Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy", J Clin Oncol, 17, pp.460~469 (1999)
- Lippman ME, "Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery", NCI Monogr, (1), pp.153~159 (1986)
- Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy", J Clin Oncol, 25, pp.4414~4422 (2007)
- Jeruss JS, "Staging of breast cancer in the neoadjuvant setting", Cancer Res, 68, pp.6477~6481 (2008)
- 김제룡, "Prognostic Factors in Patients with Stage II", III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data, 2011, pp.14(1), 39~45[DOI]
- Edge SB, "AJCC Cancer Staging Manual" (2010), Springer
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Miller M, "Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy", Ann Surg Oncol, 21, pp.3317~3323 (2014)
- Carey LA, "American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome", J Natl Cancer Inst, 97, pp.1137~1142 (2005)
- Sataloff DM, "Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome", J Am Coll Surg, 180, pp.297~306 (1995)
- Agarwal G, "Spectrum of breast cancer in Asian women", World J Surg, 31, pp.1031~1040 (2007)
- Telli ML, "Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry", Breast Cancer Res Treat, 127, pp.471~478 (2011)
- Weinreb JC, "MR imaging of the breast", Radiology, 196, pp.593~610 (1995)
- Amano G, "Correlation of three-dimensional magnetic resonance imaging with precise histopathological map concerning carcinoma extension in the breast", Breast Cancer Res Treat, 60, pp.43~55 (2000)